Company developing a broad portfolio of bioconjugate vaccines to PREvent common bacterial infections using its proprietary glycoprotein technology
GlycoVaxyn has raised €17M across 2 funding rounds from 3 investors, most recently a Series B round in Mar 2009. Based in Switzerland; active in Healthtech. Data as of 7 Aug 2026.
Timing: dormant vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
| Date |
|---|
| Stage |
|---|
| Amount |
|---|
| Investors |
|---|
| 2009-03-01 | Series B | €17M | Edmond de Rothschild Venture Capital,Index Ventures,Sofinnova Partners | View deal → |
| 2006-07-01 | Series A | €629k | Index Ventures,Sofinnova Partners | View deal → |
